Benzinga
09 Mar 2026, 14:24 UTC · 34w ago
Impact · against what's priced in
NovaBridge Biosciences is seeing a positive valuation adjustment following Phase 2a data for VIS-101 in wet AMD. The rapid, durable treatment responses and safety profile provide a concrete catalyst for a stock that has trended downward over the past year.
No priced-in read yet
What the story claims
3 claims · scored −1 bearish … +1 bullish
NovaBridge Biosciences' Phase 2a study of VIS-101 for wet AMD showed rapid, durable treatment responses and a favorable safety profile.
So whatPositive clinical data for a drug targeting a large patient population (20M+ globally) is a primary driver for biotech valuations.
More positive than 99% of claims this week
The company plans to initiate a dose-determining Phase 2b study in H2 2026 and a global Phase 3 program in 2027.
Continue reading
5 related stories
The Phase 2a study of VIS-101 showed BVCA improvements of >10 letters and CST reductions of 100-150 mm with no dose-limiting toxicity, establishing a clinical baseline for a treatment targeting 20 million patients.
Read from the article alone
Scored by the NIS engine · methodology.
More positive than 75% of claims this week
NovaBridge Biosciences shares rose 8.86% to $3.81 following the release of the study data.
More positive than 47% of claims this week
Which stocks this story touches
More positive than 73% of ticker scores this week
The company's stock jumped following positive Phase 2a study results for its wet AMD treatment VIS-101.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
MarketBeat
5h ago
−69.4%
Price is moving against the score
$1.07 vs $3.50 close before publication (Mar 6) · not market-adjusted
NBP chart →
